Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on the Effectiveness of Oxygen Therapy for Patients with Diabetic Foot Ulcers

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the effects of a treatment for people with Symptomatic Ischemic Ulcers related to Diabetes. The treatment being tested is called Hyperbaric Oxygen Therapy (HBOT), which involves breathing pure oxygen in a pressurized room or chamber. This therapy is being used in addition to standard wound care to see if it can help prevent major amputations in patients with these types of ulcers.

The purpose of the study is to determine whether HBOT is effective in treating these ulcers and to find out the best number of therapy sessions needed to achieve the desired effect. Participants in the study will receive either the oxygen treatment or a placebo, and their progress will be monitored over a period of time. The study will look at the rate of major amputations after 12 months to assess the effectiveness of the treatment.

During the study, participants will undergo regular assessments to monitor their condition and the healing of their ulcers. The treatment involves inhaling Oxygen as a medicinal gas, either in a cryogenic or compressed form, through inhalation. The study aims to provide valuable information on whether adding HBOT to standard care can improve outcomes for patients with diabetic ulcers.

The research process

The trial runs in 3 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Participation begins after meeting specific criteria, including having Type I or II diabetes and one or more deep, clinically infected lower extremity ulcers.

    A complete assessment of peripheral arterial lesions is required, using various imaging techniques.

    Inclusion follows a multidisciplinary consultation and signing of a written informed consent.

  2. Step 2

    Treatment phase

    The treatment involves the use of oxygen administered through inhalation.

    The study aims to evaluate the effectiveness of hyperbaric oxygen therapy (HBOT) as an additional treatment to standard wound care.

    The goal is to prevent major amputations and determine the optimal number of sessions needed.

  3. Step 3

    Follow-up

    The primary endpoint is the rate of major amputations after a 12-month follow-up period.

    Regular monitoring and assessments are conducted to evaluate the progress and effectiveness of the treatment.

Who can join the trial?

7 criteria

  • You must have **Type I or Type II diabetes**.
  • You need to have one or more **deep and infected ulcers** on your lower leg or foot. These ulcers should be classified as Meggit-Wagner class 3 or 4, Texas class 2C, 3C, 2D, or 3D, or WIfI class W>1, I>1, and fI>0. The ulcers should have been present for at least 4 weeks or appeared after a minor amputation due to a previous ulcer.
  • You must have **leg ischemia**, which means reduced blood flow to the leg. This is shown by an ankle blood pressure less than 70 mmHg, a toe blood pressure less than 50 mmHg, or a TcpO2 less than 40 mmHg.
  • A complete check of your **arteries** from the main artery (aorta) to the foot arteries must be done using special imaging tests like duplex ultrasonography, magnetic resonance angiography, computed tomography angiography, or intraarterial digital subtraction angiography.
  • You need to be discussed and included in the study after a **multidisciplinary consultation**, which means a team of different healthcare professionals will review your case.
  • You must be an **adult**.
  • You need to provide **written informed consent**, which means you agree to participate in the study after understanding all the details.

Who cannot join the trial?

4 criteria

  • Patients who do not have a symptomatic ischemic ulcer related to diabetes. This means the wound is not caused by poor blood flow due to diabetes.
  • Patients who are not within the specified age range for the study.
  • Patients who are not part of the clinical trial group being studied.
  • Patients who are part of a vulnerable population, which means they might need special protection or care.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

  • Amsterdam UMC

    Responsive

    The NetherlandsAmsterdam, The Netherlands

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

HBOT (Hyperbaric Oxygen Therapy) is a treatment that involves breathing pure oxygen in a pressurized room or chamber. It is used in this trial as an additional therapy to standard wound care for patients with ischemic diabetic foot ulcers (DFU). The goal is to see if this therapy can help prevent major amputations by improving the healing of the ulcers. The study aims to determine how effective HBOT is and to find out the best number of sessions needed to achieve the desired results.

What is already known about the treatment

Hyperbaric Oxygen Therapy (HBOT) – This treatment involves breathing pure oxygen in a pressurized room or chamber, which is administered to patients as a non-invasive therapy. Currently, HBOT is recognized in medical literature as a supportive treatment for various conditions, including diabetic foot ulcers. It is primarily used to enhance the healing of wounds, particularly those that are ischemic, by increasing oxygen supply to the affected tissues. At the molecular level, HBOT works by promoting angiogenesis, reducing inflammation, and enhancing the function of white blood cells. It is classified under supportive therapies that aid in wound healing and tissue repair.

Investigated diseases

Diabetic Foot Ulcer – A diabetic foot ulcer is an open sore or wound that occurs in approximately 15% of patients with diabetes and is commonly located on the bottom of the foot. It develops due to a combination of factors, such as lack of feeling in the foot, poor circulation, foot deformities, irritation, and trauma, as well as duration of diabetes. The progression of the ulcer can be slow, and it may become infected if not properly managed. Over time, the ulcer can lead to more severe complications, including tissue damage and the risk of amputation. Proper foot care and monitoring are essential to prevent the development and worsening of these ulcers.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2024-511743-26-00Estimated enrolment544 patientsSponsorAmsterdam UMC Stichting

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.